CHICAGO – No one was surprised to see immune-based therapies taking much of the air time at this year's American Society of Clinical Oncology (ASCO) meeting, since they've dominated the key scientific powwow in cancer for several years, and a fountain of outcomes showed that targeted drugs, in combination regimens as well as single agents, still have plenty going for them.